[논문]Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study

Xie, W.; Liu, J.; Wang, W.; Wang, M.; Qi, Y.; Zhao, F.; Sun, J.; Liu, J.; Li, Y.; Zhao, D.

doi:10.1016/j.ijcard.2016.04.103

Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study

International journal of cardiology, v.215, 2016년, pp.293 - 298

Xie, W. , Liu, J. , Wang, W. , Wang, M. , Qi, Y. , Zhao, F. , Sun, J. , Liu, J. , Li, Y. , Zhao, D.

Abstract ▼ AI-Helper

Background: To evaluate the association of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels with the progression of carotid atherosclerosis and identify additional PCSK9-lipoprotein-atherosclerosis pathway beyond low-density lipoprotein cholesterol (LDL-C). Methods: Among 643 participants (aged from 45 to 74years) free of cardiovascular disease at baseline, carotid ultrasound examinations were performed in 2002 (baseline) and 2012 (follow-up). None of the participants were taking lipid-lowering drugs or had detectable carotid plaques at baseline. Carotid plaque formation and total plaque area (TPA) were used to reflect 10-year progression of atherosclerosis. Results: Baseline plasma PCSK9 levels have a wide variation, ranged from 64.60-532.20ng/mL (median: 192.57ng/mL). PCSK9 levels were significantly associated with new plaque formation after adjusting for LDL-C levels and other risk factors (relative risk for per quartile increase=1.09, 95% confidence interval: 1.03-1.15). PCSK9 levels were also linearly associated with TPA after multivariate adjustment including LDL-C (P=0.008). Among participants with the lowest or second tertile of LDL-C, PCSK9 quartiles were linearly associated with TPA (P=0.021), but the association lost significance after additional adjustment for very low-density lipoprotein cholesterol (VLDL-C) tertiles (P=0.072). Further stepwise linear regression (entry, 0.05; removal, 0.05) indicated that VLDL-C tertiles could be entered into the model but PCSK9 quartiles could not. Conclusions: Plasma PCSK9 levels are associated with 10-year progression of atherosclerosis. The LDL-independent association of PCSK9 levels may through its ability to regulate VLDL-C levels. Further research is needed to systematically investigate the role of PCSK9 for the pathogenesis of atherosclerosis, beyond LDL-C metabolism.

주제어

참고문헌 (37)

J. Lipid Res. Lambert 53 2515 2012 10.1194/jlr.R026658 The PCSK9 decade

상세보기
N. Engl. J. Med. Sabatine 372 1500 2015 10.1056/NEJMoa1500858 Efficacy and safety of evolocumab in reducing lipids and cardiovascular events

상세보기
N. Engl. J. Med. Robinson 372 1489 2015 10.1056/NEJMoa1501031 Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

상세보기
J. Clin. Endocrinol. Metab. Lakoski 94 2537 2009 10.1210/jc.2009-0141 Genetic and metabolic determinants of plasma PCSK9 levels

상세보기
J. Am. Coll. Cardiol. Urban 62 1401 2013 10.1016/j.jacc.2013.07.056 Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis

상세보기
Atherosclerosis Cui 213 632 2010 10.1016/j.atherosclerosis.2010.09.027 Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population

상세보기
Atherosclerosis Cariou 211 700 2010 10.1016/j.atherosclerosis.2010.04.015 Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

상세보기
Clin. Chem. Baass 55 1637 2009 10.1373/clinchem.2009.126987 Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

상세보기
J. Lipid Res. Dubuc 51 140 2010 10.1194/jlr.M900273-JLR200 A new method for measurement of total plasma PCSK9: clinical applications

상세보기
Atherosclerosis Li 234 441 2014 10.1016/j.atherosclerosis.2014.04.001 Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease

상세보기
J. Am. Coll. Cardiol. Rosenson 64 2525 2014 10.1016/j.jacc.2014.09.042 Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

상세보기
J. Biol. Chem. Poirier 283 2363 2008 10.1074/jbc.M708098200 The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

상세보기
Vasc. Pharmacol. Werner 62 94 2014 10.1016/j.vph.2014.03.004 Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment

상세보기
Lancet Koren 380 1995 2012 10.1016/S0140-6736(12)61771-1 Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

상세보기
J. Am. Med. Assoc. Sullivan 308 2497 2012 10.1001/jama.2012.25790 Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial

상세보기
Circulation Wu 103 462 2001 10.1161/01.CIR.103.3.462 Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring

상세보기
J. Am. Med. Assoc. Liu 291 2591 2004 10.1001/jama.291.21.2591 Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese multi-provincial cohort study

상세보기
J. Am. Coll. Cardiol. Qi 65 355 2015 10.1016/j.jacc.2014.11.019 Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study

상세보기
J. Atheroscler. Thromb. Liu 21 532 2014 Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis
Stroke Zhao 39 1668 2008 10.1161/STROKEAHA.107.502807 Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing project

상세보기
J. Am. Soc. Echocardiogr. Stein 21 93 2008 10.1016/j.echo.2007.11.011

상세보기
Am. J. Epidemiol. Zou 159 702 2004 10.1093/aje/kwh090 A modified poisson regression approach to prospective studies with binary data

상세보기
BMJ Altman 326 219 2003 10.1136/bmj.326.7382.219 Interaction revisited: the difference between two estimates

상세보기
J. Am. Coll. Cardiol. Huijgen 59 1778 2012 10.1016/j.jacc.2011.12.043 Plasma PCSK9 levels and clinical outcomes in the TNT (treating to new targets) trial: a nested case-control study

상세보기
Eur. Heart J. Leander 35 370 2014 Circulating PCSK9 predicts future risk of cardiovascular events independently of established risk factors
Arterioscler. Thromb. Vasc. Biol. Roubtsova 31 785 2011 10.1161/ATVBAHA.110.220988 Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue

상세보기
Eur. Heart J. Miranda 36 51 2015 10.1093/eurheartj/ehu095 The Sirt1 activator SRT3025 provides atheroprotection in Apoe？/？ mice by reducing hepatic PCSK9 secretion and enhancing LDLR expression

상세보기
J. Lipid Res. Kuhnast 55 2103 2014 10.1194/jlr.M051326 Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

상세보기
N. Engl. J. Med. Blom 370 1809 2014 10.1056/NEJMoa1316222 A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

상세보기
J. Am. Coll. Cardiol. Lambert 63 2365 2014 10.1016/j.jacc.2014.02.538 Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects

상세보기
J. Lipid Res. Huijgen 53 979 2012 10.1194/jlr.P023994 Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia

상세보기
Stroke Herder 43 1818 2012 10.1161/STROKEAHA.111.646596 Risk factors for progression of carotid intima-media thickness and total plaque area: a 13-year follow-up study: the Tromso study

상세보기
Atherosclerosis Spence 220 34 2012 10.1016/j.atherosclerosis.2011.07.006

상세보기
Stroke Spence 33 2916 2002 10.1161/01.STR.0000042207.16156.B9 Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy

상세보기
Circulation Johnsen 112 498 2005 10.1161/CIRCULATIONAHA.104.522706 Elevated high-density lipoprotein cholesterol levels are protective against plaque progression: a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study

상세보기
Metabolism Lee 62 845 2013 10.1016/j.metabol.2013.01.005 Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects

상세보기
Atherosclerosis D'Ascenzo 226 178 2013 10.1016/j.atherosclerosis.2012.10.065 Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study

Abstract ▼ AI-Helper

주제어

참고문헌 (37)

이 논문을 인용한 문헌

관련 콘텐츠

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트